1. Lazar S, Kahlenberg JM. Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches. Annu Rev Med. 2023; 74: 339-352. doi: 10.1146/annurev-med-043021-032611.

2. Odendahl M, Jacobi A, Hansen AE, et al., Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. Journal of Immunology. 2000; 165(10): 5970-9. DOI: 10.4049/jimmunol.165.10.5970.

3. Caielli S, Wan Z, Pascual V. Systemic Lupus Erythematosus Pathogenesis: Interferon and Beyond. Annu Rev Immunol. 2023; 41: 533-560. doi: 10.1146/annurev-immunol-101921-042422.

4. Nasonov EL, Avdeeva AS, Popkova TV. New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor). Nauchcno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021; 59(5): 537-546 (In Russ.). DOI: 10.47360/1995-4484-2021-537-546.

5. Nasonov E, Soloviev S, Davidson JE, et al. Systemic lupus erythematosus and associated healthcare resource consumption in selected cities from the Russian Federation, Republic of Kazakhstan and Ukraine: the essence study. J Med Econ. 2018; 21(10): 1006-15. DOI: 10.1080/13696998.2018.1499518.

6. Tselios K, Gladman DD, Urowitz M., et al. All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971 - 2013). Ann Rheum Dis. 2019; 78(6): 802-806. doi: 10.1136/annrheumdis-2018-214802.

7. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9): 1725. DOI: 10.1002/art.1780400928.

8. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64: 2677-2686. DOI: 10.1002/art.34473.

9. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019; 78(9): 1151-9. DOI: 10.1136/annrheumdis-2018-214819.

10. Насонов Е.Л., и соавт. Проблемы ранней диагностики системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021; 59(2): 119-128. https://doi.org/10.47360/1995-4484-2021-119-128. Nasonov EL, et al. Problems of early diagnosis of systemic lupus erythematosus during the COVID-19 pandemic. Rheumatology Science and Practice. 2021; 59(2): 119-128. (In Russ.) https://doi.org/10.47360/1995-4484-2021-119-128].

11. Lambers WM, Westra J, de Leeuw K et al. Incomplete systemic lupus erythematosus - what remains after application of ACR and SLICC criteria? Arthritis Care Res. 2020; 72(5): 607-614. doi: 10.1002/acr.23894.

12. Vedove CD, et al. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009; 301(1): 99-105. doi: 10.1007/s00403-008-0895-5.

13. Иванова М.М. Системная красная волчанка. Диффузные болезни соединительной ткани. Москва: Медицина; 1994: 231 - 301.

14. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-91. PMID: 11838846.

15. Petri M, Kim MY, Kalunian KC, et al. SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15; 353(24): 2550-8. doi: 10.1056/NEJMoa051135. - in Suppl materials.

16. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005 Jun 21; 142 (12 Pt 1): 953-62.

17. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update on the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021; 80(1): 14-25. doi: 10.1136/annrheumdis-2020-218272.

18. Fanouriakis A. et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update //Annals of the rheumatic diseases. - 2024. - Т. 83. - N 1. - С. 15 - 29.

19. Gladman DD, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus. Arthritis Rheum. 1996; 39(3): 363-9. DOI: 10.1002/art.1780390303.

20. Zoma A. Musculoskeletal involvement in systemic lupus erythematosus //Lupus. - 2004. - Т. 13. - N 11. - С. 851 - 853.

21. Pisetsky D. S. et al. The categorization of pain in systemic lupus erythematosus //Rheumatic Disease Clinics. - 2021. - Т. 47. - N 2. - С. 215 - 228.

22. Ревматология: Национальное руководство/под ред. Е.Л. Насонова, В.А. Насоновой. - М.: ГЭОТАР - Медиа, 2008. - 419 - 446.

23. Pena E. et al. Systemic lupus erythematosus: a systematic review with meta-analysis on muscle strength, muscle mass, and physical function //Clinical Rheumatology. - 2023. - Т. 42. - N 5. - С. 1237 - 1248.

24. Karim M. Y. et al. Presentation and prognosis of the shrinking lung syndrome in systemic lupus erythematosus //Seminars in arthritis and rheumatism. - WB Saunders, 2002. - Т. 31. - N 5. - С. 289 - 298.

25. Panchabhai T. S. et al. A 26-year-old woman with systemic lupus erythematosus presenting with orthopnea and restrictive lung impairment //Chest. - 2016. - Т. 149. - N 1. - С. e29 - e33.

26. Rodriguez-Hernandez A. et al. Seizures in systemic lupus erythematosus: a scoping review //Seizure. - 2021. - Т. 86. - С. 161 - 167.

27. M. et al. Persistent facial oedema and erythema in a woman, an uncommon manifestation of chronic cutaneous lupus erythematosus //European Journal of Case Reports in Internal Medicine. - 2020. - Т. 7. - N 3. - С. 001462.

28. Amano S., Ohta R., Sano C. Acute facial edema in a patient with systemic lupus erythematosus //Reports. - 2021. - Т. 4. - N 3. - С. 22.

29. I. et al. Lower limb pitting edema in systemic lupus erythematosus //Rheumatology international. - 1999. - Т. 18. - N 4. - С. 159 - 160.

30. Pittau E. et al. Systemic lupus erythematosus with pitting oedema of the distal lower limbs //British journal of rheumatology. - 1998. - Т. 37. - N 1. - С. 104 - 105.

31. Rees F. et al. Burden of comorbidity in systemic lupus erythematosus in the UK, 1999 - 2012 //Arthritis care & research. - 2016. - Т. 68. - N 6. - С. 819 - 827.

32. Kuo C. F. et al. Temporal relationships between systemic lupus erythematosus and comorbidities //Rheumatology. - 2019. - Т. 58. - N 5. - С. 840 - 848.

33. Chen J. L. et al. Hematological abnormalities in systemic lupus erythematosus and clinical significance thereof: comparative analysis of 236 cases //Zhonghua yi xue za zhi. - 2007. - Т. 87. - N 19. - С. 1330 - 1333.

34. Galarza-Delgado D.A. et al. Subclinical sensorineural hearing loss in systemic lupus erythematosus: a comparative cross-sectional study //Clinical Rheumatology. - 2025. - С. 1 - 10.

35. Tseng C. H. et al. Systemic lupus erythematosus and risk of dry eye disease and corneal surface damage: A population-based cohort study //International journal of environmental research and public health. - 2023. - Т. 20. - N 5. - С. 3776.

36. Musa M. et al. Unveiling ocular manifestations in systemic lupus erythematosus //Journal of Clinical Medicine. - 2024. - Т. 13. - N 4. - С. 1047.

37. Fernandez H. et al. Mental disorders in systemic lupus erythematosus: a cohort study //Rheumatology international. - 2019. - Т. 39. - С. 1689 - 1695.

38. Hanaoka H. et al. A positive direct Coombs' test in the absence of hemolytic anemia predicts high disease activity and poor renal response in systemic lupus erythematosus //Lupus. - 2018. - Т. 27. - N 14. - С. 2274 - 2278.

39. Skare T. et al. Direct antiglobulin (Coombs) test in systemic lupus erythematosus patients //Clinical Rheumatology. - 2017. - Т. 36. - N 9. - С. 2141 - 2144.

40. Aleem A. et al. Haematological abnormalities in systemic lupus erythematosus //Acta Reumatol Port. - 2014. - Т. 39. - N 3. - С. 236-41.

41. Voulgarelis M. et al. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin //Annals of the rheumatic diseases. - 2000. - Т. 59. - N 3. - С. 217 - 222.

42. Андреичев Н.А., Балеева Л.В. Анемия хронических заболеваний //Российский медицинский журнал. - 2014. - N 2. - С. 50 - 55.

43. Бугрова О.В., Уварова Е.А. К вопросу об особенностях патогенеза анемического синдрома при системной красной волчанке //Вестник Оренбургского государственного университета. - 2004. - N 2. - С. 138 - 143.

44. Samohvalov E., Samohvalov S. The pattern of anemia in lupus //Current Topics in Anemia. - 2018.

45. Tunnicliffe DJ, Singh-Grewal D, Kim S, Craig JC, Tong A. Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines. Arthritis Care Res (Hoboken). 2015; 67(10): 1440-52. DOI: 10.1002/acr.22591.

46. Kandane-Rathnayake R. et al. Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study //Rheumatology. - 2021. - Т. 60. - N 11. - С. 5185 - 5193.

47. Abd El Hamed A. S. et al. Relation between Lymphopenia and Internal Organ Involvement in Systemic Lupus Erythematosus Patients //The Egyptian Journal of Hospital Medicine. - 2021. - Т. 85. - N 2. - С. 3609 - 3615.

48. Cabrera C. M., Castiblanque A. Associations between biological markers and haematological manifestations in patients with systemic lupus erythematosus //Clinica Chimica Acta. - 2025. - С. 120383.

49. Dooley MA, Aranow C, Ginzler EM. Review of ACR renal criteria in systemic lupus erythematosus. Lupus. 2004; 13(11): 857-860. Doi: 10.1191/0961203304lu2023oa.

50. Wilhelmus S, Alpers CE, Cook HT, et al. The Revisited Classification of GN in SLE at 10 Years: Time to Re-Evaluate Histopathologic Lesions. J Am Soc Nephrol. 2015; 26(12): 2938-46. DOI: 10.1681/ASN.2015040384.

51. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521-30. DOI: 10.1111/j.1523-1755.2004.00443.x.

52. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15: 241-50. DOI: 10.1097/01.asn.0000108969.21691.5d.

53. Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Fogo AB, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018; 93(4): 789-796. doi: 10.1016/j.kint.2017.11.023.

54. Serio I. et al. Can procalcitonin be used to distinguish between disease flare and infection in patients with systemic lupus erythematosus: a systematic literature review //Clinical rheumatology. - 2014. - Т. 33. - С. 1209 - 1215.

55. Firooz N. et al. High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus //Lupus. - 2011. - Т. 20. - N 6. - С. 588 - 597.

56. Yang Z. et al. Associations of serum urea, creatinine and uric acid with clinical and laboratory features in patients with systemic lupus erythematosus //Rheumatology international. - 2012. - Т. 32. - С. 2715 - 2723.

57. Yu Y. et al. Relationship between bilirubin and systemic lupus erythematosus: A systematic review and meta-analysis //Immunity, Inflammation and Disease. - 2023. - Т. 11. - N 12. - С. e1115.

58. Vitek L. et al. Association of systemic lupus erythematosus with low serum bilirubin levels //Scandinavian journal of rheumatology. - 2010. - Т. 39. - N 6. - С. 480 - 484.

59. Liu Y. et al. Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus //Clinical immunology. - 2015. - Т. 160. - N 2. - С. 319 - 327.

60. Xuan J. et al. Serum lipid profile in systemic lupus erythematosus //Frontiers in Immunology. - 2025. - Т. 15. - С. 1503434.

61. Schmajuk G., Yazdany J. Drug monitoring in systemic lupus erythematosus: a systematic review //Seminars in arthritis and rheumatism. - WB Saunders, 2011. - Т. 40. - N 6. - С. 559 - 575.

62. Gill J. M. et al. Diagnosis of systemic lupus erythematosus //American family physician. - 2003. - Т. 68. - N 11. - С. 2179 - 2187.

63. Ahn S. S. et al. Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus //Rheumatology international. - 2019. - Т. 39. - N 11. - С. 1937 - 1944.

64. Qu C. et al. Value of combined detection of anti-nuclear antibody, anti-double-stranded DNA antibody and C3, C4 complements in the clinical diagnosis of systemic lupus erythematosus //Experimental and therapeutic medicine. - 2019. - Т. 17. - N 2. - С. 1390 - 1394.

65. P. P. et al. Role of the anti-RO/SSA antibody in patients with systemic lupus erythematosus //. - 2025. - Т. 21. - N 3. - С. 501816.

66. Hassan A. B. et al. Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus //Scandinavian journal of rheumatology. - 2002. - Т. 31. - N 3. - С. 133 - 139.

67. Witte T. et al. Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters //Rheumatology International. - 2000. - Т. 19. - С. 107 - 111.

68. De Oliveira N. T. et al. Clinical and autoantibody profile in male and female patients with systemic lupus erythematosus: a retrospective study in 603 Brazilian patients //European Journal of Rheumatology. - 2020. - Т. 7. - N 4. - С. 164.

69. Vedove CD, et al. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009; 301(1): 99-105. doi: 10.1007/s00403-008-0895-5.

70. Kalunian K. C. et al. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus //Arthritis & Rheumatism. - 2012. - Т. 64. - N 12. - С. 4040 - 4047.

71. O., Zuily S., Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus //European journal of rheumatology. - 2015. - Т. 3. - N 2. - С. 75.

72. Chock Y. P. et al. Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: a systematic review and meta-analysis //Autoimmunity Reviews. - 2019. - Т. 18. - N 11. - С. 102395.

73. Fessler B. J. Infectious diseases in systemic lupus erythematosus: risk factors, management and prophylaxis //Best practice & research Clinical rheumatology. - 2002. - Т. 16. - N 2. - С. 281 - 291.

74. Quaglia M. et al. Viral infections and systemic lupus erythematosus: new players in an old story //Viruses. - 2021. - Т. 13. - N 2. - С. 277.

75. Панафидина Т.А., Попкова Т.В., Соловьев С.К. Мониторинг больных системной красной волчанкой: общая характеристика и дискуссионные вопросы (по материалам рекомендаций Канадской ассоциации ревматологов). Научно-практическая ревматология. 2019; 57(3): 255-264. DOI: 10.14412/1995-4484-2019-255-264. Panafidina TA, Popkova TV, Solovyev SK. Monitoring patients with systemic lupus erythematosus: general characteristics and discussion questions (according to the Canadian Rheumatology Association recommendations). Rheumatology Science and Practice. 2019; 57(3): 255-264. (In Russ.) https://doi.org/10.14412/1995-4484-2019-255-264.

76. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014; 73(6): 958-67. DOI: 10.1136/annrheumdis-2013-205139.

77. Andreoli L, Bertsias GK, Boumpas D, Tincani A, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017 Mar; 76(3): 476-485. doi: 10.1136/annrheumdis-2016-209770. PMID: 27457513.

78. Russell MD, Dey M, Flint J, Khamashta M, Giles I, et al. Audit and Guidelines Working Group. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology. 2023; 62: e48-e88. https://doi.org/10.1093/rheumatology/keac551.

79. Elmoursi A., Barmettler S. Therapeutic B-cell depletion: Mechanisms, clinical applications, and implications for secondary immunodeficiency //Journal of Allergy and Clinical Immunology. - 2024.

80. Ceccarelli F. et al. Joint involvement in systemic lupus erythematosus: from pathogenesis to clinical assessment //Seminars in arthritis and rheumatism. - WB Saunders, 2017. - Т. 47. - N 1. - С. 53 - 64.

81. Swan A., Amer H., Dieppe P. The value of synovial fluid assays in the diagnosis of joint disease: a literature survey //Annals of the rheumatic diseases. - 2002. - Т. 61. - N 6. - С. 493 - 498.

82. Sant S. M. et al. Pleuropulmonary abnormalities in patients with systemic lupus erythematosus: assessment with high resolution computed tomography, chest radiography and pulmonary function tests //Clinical and experimental rheumatology. - 1997. - Т. 15. - N 5. - С. 507 - 513.

83. Shin J. I. et al. Systemic lupus erythematosus and lung involvement: a comprehensive review //Journal of Clinical Medicine. - 2022. - Т. 11. - N 22. - С. 6714.

84. Almeida M. S. T. M. et al. Lung in systemic lupus erythematosus: a single-center experience //Open Access Library Journal. - 2022. - Т. 9. - N 9. - С. 1 - 9.

85. Lonzetti L. et al. Magnetic resonance imaging of interstitial lung diseases: A state-of-the-art review //Respiratory medicine. - 2019. - Т. 155. - С. 79 - 85.

86. Bankier A. A. et al. Discrete lung involvement in systemic lupus erythematosus: CT assessment //Radiology. - 1995. - Т. 196. - N 3. - С. 835 - 840.

87. Waki D., Onishi A., Morinobu A. Large vessel vasculopathy in a patient with systemic lupus erythematosus: a case report //Journal of Medical Case Reports. - 2019. - Т. 13. - N 1. - С. 1 - 4.

88. Behbahani S., Shahram F. Electrocardiogram and heart rate variability assessment in patients with common autoimmune diseases: a methodological review // Kardiyoloji . - 2020. - Т. 48. - N 3.

89. J. et al. Features associated with cardiac abnormalities in systemic lupus erythematosus //Lupus. - 2011. - Т. 20. - N 14. - С. 1518-1525.

90. Chang J. C. et al. Use of echocardiography at diagnosis and detection of acute cardiac disease in youth with systemic lupus erythematosus //Lupus. - 2018. - Т. 27. - N 8. - С. 1348 - 1357.

91. Amarnani R. et al. Lupus and the lungs: the assessment and management of pulmonary manifestations of systemic lupus erythematosus //Frontiers in medicine. - 2021. - Т. 7. - С. 610257.

92. Bertsias GK, Ioannidis JPA, Aringer M, Bombardieri S, Boumpas DT. et al EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010; 69(12): 2074-82. doi: 10.1136/ard.2010.130476.

93. Каратеев А.Е. Состояние слизистой оболочки желудка при системной красной волчанке и антифосфолипидном синдроме //Научно-практическая ревматология. - 2004. - N 3. - С. 23 - 26.

94. Sultan S. M., Ioannou Y., Isenberg D. A. A review of gastrointestinal manifestations of systemic lupus erythematosus //Rheumatology. - 1999. - Т. 38. - N 10. - С. 917 - 932.

95. Shevchuk S. et al. Bone mineral density in women with systemic lupus erythematosus, its association with bone turnover markers, levels of estradiol and interleukin-6. - 2020.

96. Yong J. L. C., Killingsworth M. C., Lai K. Renal biopsy pathology in a cohort of patients from southwest Sydney with clinically diagnosed systemic lupus erythematosus //International Journal of Nephrology and Renovascular Disease. - 2013. - С. 15 - 26.

97. Mokhtar G. A., Jallalah S. M. Role of electron microscopy in evaluation of native kidney biopsy: a retrospective study of 273 cases //Iranian journal of kidney diseases. - 2011. - Т. 5. - N 5. - С. 314.

98. Hill G. S. et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages //Kidney international. - 2001. - Т. 59. - N 1. - С. 304 - 316.

99. Hill G. S. et al. A new morphologic index for the evaluation of renal biopsies in lupus nephritis //Kidney international. - 2000. - Т. 58. - N 3. - С. 1160 - 1173.

100. Mosca M. et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies //Annals of the rheumatic diseases. - 2010. - Т. 69. - N 7. - С. 1269 - 1274.

101. Keeling S. O. et al. Canadian Rheumatology Association recommendations for the assessment and monitoring of systemic lupus erythematosus //The Journal of Rheumatology. - 2018. - Т. 45. - N 10. - С. 1426 - 1439.

102. Thorne I., Sutcliffe N. syndrome //British Journal of Hospital Medicine. - 2017. - Т. 78. - N 8. - С. 438 - 442.

103. Shiboski CH, Shiboski SC, Seror R, et al. 2016 ACR-EULAR Classification Criteria for primary Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol. 2017; 69: 35-45. DOI: 10.1007/s00296-018-4109-y.

104. Thorne I., Sutcliffe N. syndrome //British Journal of Hospital Medicine. - 2017. - Т. 78. - N 8. - С. 438 - 442.

105. Scheinfeld N. syndrome and systemic lupus erythematosus are distinct conditions //Dermatology online journal. - 2006. - Т. 12. - N 1.

106. Vuorialho M. et al. Salivary gland Involvement in Systemic Lupus Erythematosus: A Sialographic Study //Scandinavian journal of rheumatology. - 1984. - Т. 13. - N 1. - С. 59 - 66.

107. Whaley K. et al. Sialographic abnormalities in Sjogren's syndrome, rheumatoid arthritis, and other arthritides and connective tissue diseases. A clinical and radiological investigation using hydrostatic sialography //Clinical Radiology. - 1972. - Т. 23. - N 4. - С. 474 - 482.

108. van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014; 73(6): 958-67. DOI: 10.1136/annrheumdis-2013-205139.

109. Ruiz-Arruza I, Barbosa C, Ugarte A, Ruiz-Irastorza G. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev. 2015 Oct; 14(10): 875-9. doi: 10.1016/j.autrev.2015.05.011. Epub 2015 Jun 1. PMID: 26044819.

110. Mok T. C., Mok C. C. Glucocorticoid in systemic lupus erythematosus: the art beyond science //Expert Review of Clinical Immunology. - 2025.

111. van Vollenhoven R. F. et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force //Lupus science & medicine. - 2021. - Т. 8. - N 1. - С. e000538.

112. Bertsias G. et al. A path to Glucocorticoid Stewardship: a critical review of clinical recommendations for the treatment of systemic lupus erythematosus //Rheumatology. - 2024. - Т. 63. - N 7. - С. 1837 - 1849.

113. Mok C. C. et al. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus //The Lancet Rheumatology. - 2021. - Т. 3. - N 7. - С. e517 - e531.

114. Новиков П.И., Моисеев С.В. Глюкокортикосте - роиды при системной красной волчанке: перспективы стероидосберегающей терапии. Клин фармакол. тер. 2022; 31(4): 18-27.

115. Wallace DJ, Goldfinger D, Pepkowitz SH, Fichman M, Metzger AL, Schroeder JO, Euler HH. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apher. 1998; 13(4): 163-6. DOI: 10.1002/(sici) 1098-1101(1998) 13:4<163::aid-jca4>3.0.co;2-1.

116. Pego-Reigosa J.M. et al. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review //Arthritis care & research. - 2013. - Т. 65. - N 11. - С. 1775 - 1785.

117. Petri M, Brodsky RA, Jones RJ, Gladstone D, Fillius M, Magder LS. High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum. 2010; 62(5): 1487-93. DOI: 10.1002/art.27371.

118. Chan TM, Tse KC, Tang CS, Mok MY, Li FK; Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005; 16(4): 1076-84. DOI: 10.1681/ASN.2004080686.

119. Tian M. et al. Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis //Medicine. - 2017. - Т. 96. - N 51. - С. e9408.

120. Houssiau F. A. et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide //Arthritis & Rheumatism. - 2002. - Т. 46. - N 8. - С. 2121 - 2131.

121. Walsh M. et al. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis //Clinical Journal of the American Society of Nephrology. - 2007. - Т. 2. - N 5. - С. 968 - 975.

122. Sakthiswary R., Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy //Lupus. - 2014. - Т. 23. - N 3. - С. 225 - 235.

123. Fortin P. R. et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial //Arthritis Care & Research. - 2008. - Т. 59. - N 12. - С. 1796 - 1804.

124. Carneiro J. R., Sato E. I. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus //The Journal of rheumatology. - 1999. - Т. 26. - N 6. - С. 1275 - 1279.

125. Cai T. et al. Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: a systematic review and meta-analysis of cohort studies //Lupus. - 2022. - Т. 31. - N 14. - С. 1714 - 172.

126. Shipman W. D. et al. An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: a systematic review //Journal of the American Academy of Dermatology. - 2020. - Т. 82. - N 3. - С. 709 - 722.

127. L, et al. EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025 Apr 25: S0003-4967(25) 00818-0.

128. M., Villiger P. M. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus //Lupus. - 2001. - Т. 10. - N 3. - С. 135 - 139. MLA.

129. Di Franco M. et al. Pain and systemic lupus erythematosus //Reumatismo. - 2014. - Т. 66. - N 1. - С. 33 - 38.

130. Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumabin active systemic lupus erythematosus (TULIP-1): a randomized, controlled, phase 3 trial. Lancet Rheumatol. 2019; 1: e208-e219.

131. Morand E, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus. N Engl J Med. 2020; 382: 211-221.

132. Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an Anti-Interferon- Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017; 69(2): 376-386.

133. Bruce I. N. et al. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study //The Lancet Rheumatology. - 2021. - Т. 3. - N 2. - С. e101 - e110.

134. Furie R, Rovin B H, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med 2020; 383: 1117-28. DOI: 10.1056/NEJMoa2001180.

135. Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014; 41(2): 300-9. DOI: 10.3899/jrheum.121368.

136. Duxbury B., Combescure C., Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis //Lupus. - 2013. - Т. 22. - N 14. - С. 1489 - 1503.

137. Lan L., Han F., Chen J. Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis //Journal of Zhejiang University SCIENCE B. - 2012. - Т. 13. - С. 731 - 744.

138. Illei G. G. et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study //Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. - 2010. - Т. 62. - N 2. - С. 542 - 552.

139. Yadav S., Sharma V., Balakrishnan C. Tocilizumab Therapy for Treatment-Resistant Systemic Lupus Erythematosus with Elevated IL-6 and CRP Levels: A Case Report //SN Comprehensive Clinical Medicine. - 2023. - Т. 5. - N 1. - С. 199.

140. Danion F. et al. Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease //Lupus. - 2016. - Т. 25. - N 13. - С. 1440 - 1447.

141. Morand E. F. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) //The Lancet. - 2023. - Т. 401. - N 10381. - С. 1001 - 1010.

142. Petri M. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) //The Lancet. - 2023. - Т. 401. - N 10381. - С. 1011 - 1019.

143. Hasni S. A. et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus //Nature communications. - 2021. - Т. 12. - N 1. - С. 3391.

144. Merrill J. T. et al. Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: A phase 2 randomized controlled trial //Arthritis & Rheumatology. - 2024. - Т. 76. - N 10. - С. 1518 - 1529.

145. Skaarup L. et al. A systematic overview of contraindications and special warnings for biologic and targeted synthetic disease modifying antirheumatic drugs: establishing a framework to create a "Safety Checklist" //Drug Safety. - 2024. - Т. 47. - N 11. - С. 1075 - 1093.

146. Sakthiswary R., D'Cruz D. Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis //Medicine. - 2014. - Т. 93. - N 16. - С. e86.

147. Camara I. et al. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre //Clin Exp Rheumatol. - 2014. - Т. 32. - N 1. - С. 41-7.

148. Середавкина Н.В., Решетняк Т.М., Насонов Е.Л. Место внутривенного иммуноглобулина при ревматических заболеваниях. Современная ревматология. 2015; 9(4): 59-67.

149. Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020 Dec 5; 59 (Suppl5): v69-v81. doi: 10.1093/rheumatology/keaa403. PMID: 33280011; PMCID: PMC7719039.

150. Kronbichler A, Brezina B, Quintana LF, Jayne DR. Efficacy of plasma exchange and immunoadsorption in systemic lupus erythematosus and antiphospholipid syndrome: A systematic review. Autoimmun Rev. 2016; 15(1): 38-49. DOI: 10.1016/j.autrev.2015.08.010.

151. SCHROEDER J. O., EULER H. H., H. Synchronization of plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus //Annals of internal medicine. - 1987. - Т. 107. - N 3. - С. 344 - 346.

152. Abe T. et al. The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis //Therapeutic Apheresis and Dialysis. - 2021. - Т. 25. - N 6. - С. 728 - 876.

153. Fairley J. L. et al. Management of cutaneous manifestations of lupus erythematosus: a systematic review //Seminars in arthritis and rheumatism. - WB Saunders, 2020. - Т. 50. - N 1. - С. 95 - 127.

154. Mok C. C. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review //Scandinavian journal of rheumatology. - 2007. - Т. 36. - N 5. - С. 329 - 337.

155. Fairley J. L. et al. Management of cutaneous manifestations of lupus erythematosus: a systematic review //Seminars in arthritis and rheumatism. - WB Saunders, 2020. - Т. 50. - N 1. - С. 95 - 127.

156. Mojumdar S. K. et al. Comparison of Efficacy of Mesna and Hydration with Only Hydration in the Prevention of Cyclophosphamide Induced Hemorrhagic Cystitis in Rheumatic Diseases //Journal of Brahmanbaria Medical College. - 2021. - Т. 3. - N 2. - С. 3 - 7.

157. Koo T. Y. et al. Water intoxication following low-dose intravenous cyclophosphamide //Electrolytes & Blood Pressure: E & BP. - 2007. - Т. 5. - N 1. - С. 50 - 54.

158. West N. J. Prevention and treatment of hemorrhagic cystitis //Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. - 1997. - Т. 17. - N 4. - С. 696 - 706.

159. Grossman J. M. Lupus arthritis //Best practice & research Clinical rheumatology. - 2009. - Т. 23. - N 4. - С. 495 - 506.

160. Tam L. S. et al. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus //Lupus. - 2004. - Т. 13. - N 8. - С. 601 - 604.

161. Torre O., Harari S. Pleural and pulmonary involvement in systemic lupus erythematosus //La Presse . - 2011. - Т. 40. - N 1. - С. e41 - e51.

162. Imazio M. Pericardial involvement in systemic inflammatory diseases //Heart. - 2011. - Т. 97. - N 22. - С. 1882 - 1892.

163. Kontzias A., Barkhodari A., Yao Q. P. Pericarditis in systemic rheumatologic diseases //Current Cardiology Reports. - 2020. - Т. 22. - С. 1 - 12.

164. Wang D. Y. Diagnosis and management of lupus pleuritis //Current opinion in pulmonary medicine. - 2002. - Т. 8. - N 4. - С. 312 - 316.

165. Kokori S. I. G. et al. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus //The American journal of medicine. - 2000. - Т. 108. - N 3. - С. 198 - 204.

166. Santacruz J. C. et al. A practical perspective of the hematologic manifestations of systemic lupus erythematosus //Cureus. - 2022. - Т. 14. - N 3.

167. Mak A., Mok C. C. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus //Lupus. - 2005. - Т. 14. - N 10. - С. 856 - 858.

168. So M. W. et al. Successful rituximab treatment of refractory hemophagocytic lymphohistiocytosis and autoimmune hemolytic anemia associated with systemic lupus erythematosus //Modern Rheumatology. - 2014. - Т. 24. - N 5. - С. 855 - 857.

169. Serris A. et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults //American journal of hematology. - 2018. - Т. 93. - N 3. - С. 424 - 429.

170. Boumpas D. T. et al. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus //Annals of Internal Medicine. - 1990. - Т. 112. - N 9. - С. 674 - 677.

171. Galanopoulos N., Christoforidou A., Bezirgiannidou Z. Lupus thrombocytopenia: pathogenesis and therapeutic implications //Mediterranean Journal of Rheumatology. - 2017. - Т. 28. - N 1. - С. 20 - 26.

172. Hepburn A. L., Narat S., Mason J. C. The management of peripheral blood cytopenias in systemic lupus erythematosus //Rheumatology. - 2010. - Т. 49. - N 12. - С. 2243 - 2254.

173. Fanouriakis A. et al. Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study //Lupus. - 2016. - Т. 25. - N 6. - С. 627 - 636.

174. Boumpas D. T. et al. Pulse cyclophosphamide for severe neuropsychiatric lupus //QJM: An International Journal of Medicine. - 1991. - Т. 81. - N 3. - С. 975 - 984.

175. Magro-Checa C. et al. Management of neuropsychiatric systemic lupus erythematosus: current approaches and future perspectives //Drugs. - 2016. - Т. 76. - С. 459 - 483.

176. Tokunaga M. et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system //Annals of the rheumatic diseases. - 2007. - Т. 66. - N 4. - С. 470 - 475.

177. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERAEDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020; 79(6): 713-23. DOI: 10.1136/annrheumdis2020-216924.

178. Anders H. J. et al. The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021 //Nephrology Dialysis Transplantation. - 2023. - Т. 38. - N 3. - С. 551 - 561.

179. Illei G. G. et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis //Annals of internal medicine. - 2001. - Т. 135. - N 4. - С. 248 - 257.

180. Gadakchi L. et al. Efficacy and safety of mycophenolate mofetil versus intravenous pulse cyclophosphamide as induction therapy in proliferative lupus nephritis //Iranian Journal of Kidney Diseases. - 2018. - Т. 12. - N 5. - С. 288.

181. Ginzler E. M. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis //New England Journal of Medicine. - 2005. - Т. 353. - N 21. - С. 2219 - 2228.

182. Ohkubo N. et al. Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis //Modern Rheumatology. - 2022. - Т. 32. - N 6. - С. 1077 - 1085.

183. Henderson L. K. et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials //American journal of kidney diseases. - 2013. - Т. 61. - N 1. - С. 74 - 87.

184. Tam L. S. et al. Long-term treatment of lupus nephritis with cyclosporin A //QJM: monthly journal of the Association of Physicians. - 1998. - Т. 91. - N 8. - С. 573 - 580.

185. Deng J. et al. A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis //The Tohoku journal of experimental medicine. - 2012. - Т. 227. - N 4. - С. 281 - 288.

186. Hu W. et al. Cyclosporine A in treatment of membranous lupus nephropathy //Chinese medical journal. - 2003. - Т. 116. - N 12. - С. 1827 - 1830.

187. Yang T. H. et al. Cyclosporine for the treatment of lupus nephritis in patients with systemic lupus erythematosus //Clinical Nephrology. - 2018. - Т. 89. - N 4. - С. 277.

188. Stolyar L., Lahita R. G., Panush R. S. Rituximab use as induction therapy for lupus nephritis: a systematic review //Lupus. - 2020. - Т. 29. - N 8. - С. 892 - 912.

189. Lanata C. M. et al. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis //Lupus. - 2010. - Т. 19. - N 8. - С. 935 - 940.

190. Hannah J., Casian A., D'Cruz D. Tacrolimus use in lupus nephritis: a systematic review and meta-analysis //Autoimmunity reviews. - 2016. - Т. 15. - N 1. - С. 93 - 101.

191. Furie R. A. et al. Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis //New England Journal of Medicine. - 2025.

192. Furie R. A. et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial //Annals of the rheumatic diseases. - 2022. - Т. 81. - N 1. - С. 100 - 107.

193. Askanase A. D., Dall'Era M., Almaani S. Insights into future management of lupus nephritis //Frontiers in Lupus. - 2024. - Т. 2. - С. 1334932.

194. M. S. F. et al. Early predictors of renal outcome in patients with proliferative lupus nephritis: a 36-month cohort study //Rheumatology. - 2021. - Т. 60. - N 11. - С. 5134 - 5141.

195. Moroni G. et al. The long-term outcome of 93 patients with proliferative lupus nephritis //Nephrology Dialysis Transplantation. - 2007. - Т. 22. - N 9. - С. 2531 - 2539.

196. Mak A. Orthopedic surgery and its complication in systemic lupus erythematosus //World Journal of Orthopedics. - 2014. - Т. 5. - N 1. - С. 38.

197. Parodis I. et al. EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis //Annals of the rheumatic diseases. - 2024. - Т. 83. - N 6. - С. 720 - 729.

198. Mosca M. et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies //Annals of the rheumatic diseases. - 2010. - Т. 69. - N 7. - С. 1269 - 1274.

199. Keeling S. O. et al. Canadian Rheumatology Association recommendations for the assessment and monitoring of systemic lupus erythematosus //The Journal of Rheumatology. - 2018. - Т. 45. - N 10. - С. 1426 - 1439.

200. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010; 8: 237-42. doi: 10.1111/j.1538-7836.2009.03674.x.].

201. Ballocca F, D'Ascenzo F, Moretti C, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015; 22(11): 1435-41.

202. J. Systemic lupus erythematosus and cardiovascular disease. J Intern Med. 2023; 293(1): 48-62.

203. Kostopoulou M, Nikolopoulos D, Parodis I, Bertsias G. Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention. Curr Vasc Pharmacol. 2020; 18(6): 549-565.

204. Fanouriakis A. et al. Update on the diagnosis and management of systemic lupus erythematosus //Annals of the rheumatic diseases. - 2021. - Т. 80. - N 1. - С. 14 - 25.

205. Bernatsky S, Ramsey-Goldman R, Joseph L. et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann. Rheum. Dis. 2014; 73(1): 138-42. DOI: 10.1136/annrheumdis-2012-202099.

206. Andreoli L, Bertsias GK, Agmon-Levin N et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017 Mar; 76(3): 476-485.

207. Ladouceur A. et al. Cancer and systemic lupus erythematosus //Rheumatic Disease Clinics. - 2020. - Т. 46. - N 3. - С. 533 - 550.

208. Andreoli L, Bertsias GK, Boumpas D, Tincani A, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017 Mar; 76(3): 476-485.

209. Smyth A, Oliveira GH, Lahr BD, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010; 5(11): 2060-8. DOI: 10.2215/CJN.00240110.

210. Andreolia L, Gerardia MC, Fernandesb M, Bortoluzzic A, Tincania A, et al. Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. Autoimmunity Reviews. 2019; 18: 164-176.

211. Russell M. D. et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids //Rheumatology. - 2023. - Т. 62. - N 4. - С. e48 - e88.

212. M. et al. Anti-inflammatory and immunosuppressive drugs and reproduction //Arthritis research & therapy. - 2006. - Т. 8. - С. 1 - 19.

213. Buchanan N. M. et al. Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases //Annals of the Rheumatic Diseases. - 1996. - Т. 55. - N 7. - С. 486 - 488.

214. Gordon C., Kilby M. D. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome //Lupus. - 1998. - Т. 7. - N 7. - С. 429 - 433.

215. Saad A. F., Pacheco L. D., Saade G. R. Immunosuppressant medications in pregnancy //Obstetrics & Gynecology. - 2022. - С. 10.1097.

216. Jiang Y. et al. Calcineurin inhibitors in the treatment of systemic lupus erythematosus during pregnancy: A narrative review with emphasis on efficacy and safety //European Journal of Obstetrics & Gynecology and Reproductive Biology. - 2024. - Т. 294. - С. 148 - 155.

217. Giannakaki A. G. et al. Current Approaches to the Management of Rheumatic Diseases in Pregnancy: Risk Stratification, Therapeutic Advances, and Maternal-Fetal Outcomes //Journal of Personalized Medicine. - 2025. - Т. 15. - N 9. - С. 406.

218. Ertenli. et al. AB0079 cyclophosphamide exposure during pregnancy: two cases //Annals of the Rheumatic Diseases. - 2001. - Т. 60. - С. A53.

219. Danve A., Perry L., Deodhar A. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus-a case report //Seminars in arthritis and rheumatism. - WB Saunders, 2014. - Т. 44. - N 2. - С. 195 - 197.

220. Kao J. H. et al. Pregnancy outcomes in patients treated with belimumab: report from real-world experience //Seminars in Arthritis and Rheumatism. - WB Saunders, 2021. - Т. 51. - N 5. - С. 963 - 968.

221. Colquhoun M. et al. Rituximab administration during the second trimester of pregnancy for systemic lupus erythematosus: Case report and review of the literature on rheumatic disease //Modern Rheumatology Case Reports. - 2022. - Т. 6. - N 2. - С. 173 - 177.

222. Kasturi S., Sammaritano L. R. Corticosteroids in lupus //Rheumatic Disease Clinics. - 2016. - Т. 42. - N 1. - С. 47 - 62.

223. Somerset D. A. et al. Intravenous immunoglobulin therapy in compromised pregnancies associated with antiphospholipid antibodies and systemic lupus erythematosus //European Journal of Obstetrics & Gynecology and Reproductive Biology. - 1998. - Т. 79. - N 2. - С. 227 - 229.

224. McDonald E. G. et al. Monitoring of systemic lupus erythematosus pregnancies: a systematic literature review //The Journal of Rheumatology. - 2018. - Т. 45. - N 10. - С. 1477 - 1490.

225. Bass AR, Chakravarty E, Akl EA, Bingham CO, Cappelli LC., et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients with Rheumatic and Musculoskeletal Diseases. Arthritis Care Res. 2023; 75: 449-464.

226. Furer V. et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases //Annals of the rheumatic diseases. - 2020. - Т. 79. - N 1. - С. 39 - 52.